213 related articles for article (PubMed ID: 31704556)
21. Costs of Definitive Chemoradiation, Surgery, and Adjuvant Radiation Versus De-Escalated Adjuvant Radiation per MC1273 in HPV+ Cancer of the Oropharynx.
Waddle MR; Ma DJ; Visscher SL; Borah BJ; May JM; Price KA; Moore EJ; Patel SH; Hinni ML; Chintakuntlawar AV; Garcia JJ; Graner DE; Neben-Wittich MA; Garces YI; Hallemeier CL; Price DL; Kasperbauer JL; Janus JR; Foote RL; Miller RC
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):396-402. PubMed ID: 33359567
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus in oropharyngeal squamous cell carcinoma in South-Eastern Norway: prevalence, genotype, and survival.
Fossum GH; Lie AK; Jebsen P; Sandlie LE; Mork J
Eur Arch Otorhinolaryngol; 2017 Nov; 274(11):4003-4010. PubMed ID: 28933005
[TBL] [Abstract][Full Text] [Related]
23. Extranodal extension is a strong prognosticator in HPV-positive oropharyngeal squamous cell carcinoma.
Bauer E; Mazul A; Chernock R; Rich J; Jackson RS; Paniello R; Pipkorn P; Oppelt P; Gay H; Daly M; El-Mofty S; Thorstad W; Adkins D; Zevallos J
Laryngoscope; 2020 Apr; 130(4):939-945. PubMed ID: 31077394
[TBL] [Abstract][Full Text] [Related]
24. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer.
Chera BS; Kumar S; Beaty BT; Marron D; Jefferys S; Green R; Goldman EC; Amdur R; Sheets N; Dagan R; Hayes DN; Weiss J; Grilley-Olson JE; Zanation A; Hackman T; Blumberg JM; Patel S; Weissler M; Tan XM; Parker JS; Mendenhall W; Gupta GP
Clin Cancer Res; 2019 Aug; 25(15):4682-4690. PubMed ID: 31088830
[TBL] [Abstract][Full Text] [Related]
25. Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era.
Keane FK; Chen YH; Neville BA; Tishler RB; Schoenfeld JD; Catalano PJ; Margalit DN
Cancer; 2015 Aug; 121(15):2594-602. PubMed ID: 25873094
[TBL] [Abstract][Full Text] [Related]
26. Management of the neck after definitive chemoradiation in patients with HPV-associated oropharyngeal cancer: An institutional experience.
Wotman M; Ghaly M; Massaro L; Tham T; Seetharamu N; Kamdar D; Frank D; Kraus D; Teckie S
Am J Otolaryngol; 2019; 40(5):684-690. PubMed ID: 31229365
[TBL] [Abstract][Full Text] [Related]
27. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.
Zumsteg ZS; Lok BH; Ho AS; Drill E; Zhang Z; Riaz N; Shiao SL; Ma J; McBride SM; Tsai CJ; Baxi SS; Sherman EJ; Lee NY
Cancer; 2017 Apr; 123(8):1345-1353. PubMed ID: 27984656
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of definitive local therapy with intensity-modulated radiation therapy in elderly patients ≥70 years with HPV-associated oropharyngeal cancer.
Baliga S; Yildiz V; Barve R; Farag A; Bhateja P; Gogineni E; Mitchell D; Konieczkowski D; Grecula J; Ma SJ; Zhu S; Liu X; Bonomi M; Blakaj DM
J Med Virol; 2023 Dec; 95(12):e29293. PubMed ID: 38054393
[TBL] [Abstract][Full Text] [Related]
29. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation.
Platek AJ; Jayaprakash V; Merzianu M; Platek ME; Cohan DM; Hicks WL; Marimuthu SP; Winslow TB; Gupta V; Arshad H; Kuriakose MA; Dibaj S; Marshall JR; Reid ME; Warren GW; Singh AK
Laryngoscope; 2016 Dec; 126(12):2733-2738. PubMed ID: 27346612
[TBL] [Abstract][Full Text] [Related]
30. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.
Kelly JR; Park HS; An Y; Yarbrough WG; Contessa JN; Decker R; Mehra S; Judson BL; Burtness B; Husain Z
Oral Oncol; 2018 Apr; 79():64-70. PubMed ID: 29598952
[TBL] [Abstract][Full Text] [Related]
31. Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.
Nakano T; Yamamoto H; Nakashima T; Nishijima T; Satoh M; Hatanaka Y; Shiratsuchi H; Yasumatsu R; Toh S; Komune S; Oda Y
Hum Pathol; 2016 Apr; 50():51-61. PubMed ID: 26997438
[TBL] [Abstract][Full Text] [Related]
32. Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.
Spreafico A; Huang SH; Xu W; Granata R; Liu CS; Waldron JN; Chen E; Ringash J; Bayley A; Chan KK; Hope AJ; Cho J; Razak AA; Hansen A; Jang R; Perez-Ordonez B; Weinreb I; Bossi P; Orlandi E; Licitra LF; Song Y; O'Sullivan B; Siu LL; Kim J
Eur J Cancer; 2016 Nov; 67():174-182. PubMed ID: 27669504
[TBL] [Abstract][Full Text] [Related]
33. Human Papillomavirus-Negative Oropharyngeal Cancer Survival Outcomes Based on Primary Treatment: National Cancer Database Analysis.
Shama M; Al-Qurayshi Z; Dahl M; Amdur RJ; Bates J; Mendenhall W; Hitchcock K; Festa BM; Ghanem T; Dziegielewski PT
Otolaryngol Head Neck Surg; 2022 Jul; 167(1):100-108. PubMed ID: 34546828
[TBL] [Abstract][Full Text] [Related]
34. Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: The Dana Farber Experience.
Lorch JH; Hanna GJ; Posner MR; O'Neill A; Thotakura VL; Limaye SA; Rabinowits G; Sher DJ; Tishler RB; Haddad RI
Head Neck; 2016 Apr; 38 Suppl 1():E1618-24. PubMed ID: 26614576
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival and swallowing outcomes in advanced stage oropharyngeal squamous cell carcinomas.
Clark JM; Holmes EM; O'Connell DA; Harris J; Seikaly H; Biron VL
Papillomavirus Res; 2019 Jun; 7():1-10. PubMed ID: 30267774
[TBL] [Abstract][Full Text] [Related]
36. Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC.
Sanford NN; Hwang WL; Pike LRG; Lam AC; Royce TJ; Mahal BA
Oral Oncol; 2019 Nov; 98():28-34. PubMed ID: 31536843
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of primary radiotherapy versus surgery in elderly patients with locally advanced oropharyngeal squamous cell carcinoma.
Sher DJ; Yan J; Day A; Sumer BD; Pham NL; Khan S; Zhu H
Oral Oncol; 2019 Jan; 88():18-26. PubMed ID: 30616791
[TBL] [Abstract][Full Text] [Related]
38. Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.
Swain M; Kannan S; Srinivasan S; Agarwal JP; Gupta T
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):786-795. PubMed ID: 35387752
[TBL] [Abstract][Full Text] [Related]
39. HPV-Positive Oropharyngeal Carcinoma: A Systematic Review of Treatment and Prognosis.
Wang MB; Liu IY; Gornbein JA; Nguyen CT
Otolaryngol Head Neck Surg; 2015 Nov; 153(5):758-69. PubMed ID: 26124261
[TBL] [Abstract][Full Text] [Related]
40. Treatment trends for advanced oropharyngeal squamous cell carcinoma in the era of human papillomavirus.
Mirza FA; Johnson CZ; Byrd JK; Albergotti WG
Head Neck; 2021 Nov; 43(11):3476-3492. PubMed ID: 34499392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
